Context:

The Supreme Court declined to hear challenges from drugmakers unhappy with Medicare’s new price-negotiation authority, leaving lower-court rulings intact and the program on track to set prices for selected drugs. The negotiation rollout, created by the 2022 Inflation Reduction Act, aims to curb high costs by requiring annual price talks with manufacturers, with the first agreements effective in 2026. Critics argue the policy shifts leverage away from insurers and PBMs, while supporters say it delivers tangible savings to beneficiaries. With no court intervention in sight and no explicit sunset, the program’s trajectory depends on congressional action for any potential changes.

Dive Deeper:

• The Supreme Court rejected the manufacturers' appeals in a decision that left intact lower-court rulings dismissing the suit, effectively allowing the price-negotiation program to proceed without disruption.

• The policy, enacted under the Inflation Reduction Act, requires the government to negotiate prices for high-cost Medicare drugs on an annual basis, with the first negotiated prices slated for 2026.

• As of the latest round, the government has secured lower prices on 25 Medicare-covered prescriptions, including GLP-1 drugs like Ozempic, Rybelsus, and Wegovy, highlighting the program’s initial impact.

• In January, regulators outlined a plan for a third round of drug targets, which would expand the universe of drugs subject to negotiation, potentially increasing savings and coverage scope.

• Pharma companies contend the approach shifts focus from manufacturers to insurers and PBMs, arguing for a different pathway to controlling costs, though legislative action would be required to halt or alter the program.

• Abroad political dynamics add to the program’s front-line politics: the law passed without Republican votes, while the administration remains supportive of leveraging negotiation leverage to curb drug spending.

• Because the statute does not specify an end date, the program could continue indefinitely unless Congress intervenes, making future changes contingent on legislative action rather than court rulings.